Do you want to read an article? Please log in or register.
Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study
Uveitis
Related content
Macular Diseases
Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab
Clin Exp Ophthalmol.
Spooner K, Fraser-Bell S, Hong T, Chang A
doi: 10.1111/ceo.13636.
COMMENTED
Glaucoma and Ocular Pressure
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up
★ 3
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
★ 2
Recommended by
Dr Katarzyna Konieczka, Faculty Member
JAMA Ophthalmol
Kass MA, Heuer DK, Higginbotham EJ, Parrish RK, Khanna CL, Brandt JD, Soltau JB, Johnson CA, Keltner JL, Huecker JB, Wilson BS, Liu L, Miller JP, Quigley HA, Gordon MO, Ocular Hypertension Study Group.
doi: 10.1001/jamaophthalmol.2021.0341
RECOMMENDED
Cornea and Corneal DiseasesLenses
Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization
Ocul Surf.
Yin J, Jacobs DS
doi: 10.1016/j.jtos.2018.11.008.
COMMENTED
Glaucoma and Ocular Pressure
Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution
Am J Ophthalmol.
Kahook MY, Serle JB, Mah FS, Kim T, Raizman MB, Heah T, Ramirez-Davis N, Kopczynski CC, Usner DW, Novack GD8; ROCKET-2 Study Group
doi: 10.1016/j.ajo.2019.01.003.
Uveitis
Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis
Cochrane Database Syst Rev.
Barry RJ, Tallouzi MO, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK
doi: 10.1002/14651858.
Macular Diseases
Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study
Acta Ophthalmol.
Granstam E, Rosenblad A, Modher Raghib A, Granström T, Eriksson JW, Lindholm Olinder A, Leksell J
doi: 10.1111/aos.14290.
Uveitis
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
Lancet.
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP
doi: 10.1016/
Macular DiseasesRetinal DiseasesUveitis
Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)
Br J Ophthalmol
Khurana RN, Merrill P, Yeh S, Suhler E, Barakat MR, Uchiyama E, Henry CR, Shah M, Wang RC, Kapik B, Ciulla T
doi: 10.1136/bjophthalmol-2020-317560
Uveitis
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis
Clin Exp Rheumatol.
Tosi GM, Sota J, Vitale A, Rigante D, Emmi G, Lopalco G, Guerriero S, Orlando I, Iannone F, Frediani B, Angotti R, Messina M, Galeazzi M, Vannozzi L, Cantarini L,
Fabiani C